In 2023, Microport Cardioflow Medtech completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).
However, Microport Cardioflow Medtech has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2023 | 2022 | 2021 | 2020-2019 |
|---|---|---|---|---|
Total Scope 1 | 267.5a | 348.4a | 7.16a | |
Total Scope 2 | ||||
Unspecified Calculation Method | 3,078.4a | 5,159.6a | 2,912a | |
Total Scope 3 | N/A | N/A | N/A | |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 5.6545a | 1.3879a | 0.0357a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2023, the total operational greenhouse gas (GHG) emissions of Microport Cardioflow Medtech amounted to 3,345.9 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2022, the total operational greenhouse gas (GHG) emissions of Microport Cardioflow Medtech decreased by 39.25%, showing that the company has made progress in taking action to reduce the climate impact of its operations.a
In 2023, the total Scope 1 emissions of Microport Cardioflow Medtech were 267.5 metric tons of CO₂ equivalent (tCO₂e).a
Since 2020, Microport Cardioflow Medtech's Scope 1 emissions have increased by 5,702.6%, reflecting a rising long-term trend in Scope 1 emissions over time.ab
Compared to the previous year (2022), Microport Cardioflow Medtech's Scope 1 emissions decreased by 23.22%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.a
In 2023, Microport Cardioflow Medtech reported Scope 2 greenhouse gas (GHG) emissions of 3,078.4 tCO₂e without specifying the calculation method.a
Since 2020, Microport Cardioflow Medtech's Scope 2 greenhouse gas (GHG) emissions (Unspecified Calculation Method) have increased by 23.83%, reflecting a rising long-term trend in Scope 2 emissions over time.ab
Compared to the previous year (2022), Microport Cardioflow Medtech's Scope 2 emissions (Unspecified Calculation Method) fell by 40.34% in 2023, showing that the company has made progress in taking action to reduce the climate impact of its energy consumption.a
In 2023, Microport Cardioflow Medtech reported its Scope 2 emissions using an unspecified methodology.a
In 2023, Microport Cardioflow Medtech reported Scope 1 greenhouse gas (GHG) emissions of 267.5 tCO₂e and total revenues of USD 47 millions. This translates into an emissions intensity of 5.65 tCO₂e per millions USD.a
In 2023, Microport Cardioflow Medtech reported a Scope 1 emissions intensity of 5.65 tCO₂e per millions USD. Compared to the peer group median of 2.58, this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors.a
In 2023, Microport Cardioflow Medtech ranked 22 out of 24 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
This places Microport Cardioflow Medtech among the least efficient performers, with one of the highest emissions intensities in its sector.a